Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 (or mRNA (Moderna mRNA-1273 or Pfizer/BNT) and Novavax NVX-CoV2373 COVID-19 Vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years With and Without HIV Infection in 3 African Countries Kenya, Democratic Republic of Congo, and Rwanda.

NCT07408297 is registered in ClinicalTrials.gov with Victoria Biomedical Research Institute as lead sponsor.

NCT NCT07408297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07408297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 (or mRNA (Moderna mRNA-1273 or Pfizer/BNT) and Novavax NVX-CoV2373 COVID-19 Vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years With and Without HIV Infection in 3 African Countries Kenya, Democratic Republic of Congo, and Rwanda.
Lead sponsor
Victoria Biomedical Research Institute
Phase
Phase 2
Overall status
Completed
Start date
May 18, 2022
Completion date
June 27, 2024
Enrollment
1,919 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid -19, sars cov 2 infection